title: Optimized mouse model for the imaging of tumor metastasis upon experimental therapy.
abstract: Development of new cancer treatments focuses increasingly on the relation of cancer tissue with its microenvironment. A major obstacle for the development of new anti-cancer therapies has been the lack of relevant animal models that would reproduce all the events involved in disease progression from the early-stage primary tumor until the development of mature metastatic tissue. To this end, we have developed a readily imageable mouse model of colorectal cancer featuring highly reproducible formation of spontaneous liver metastases derived from intrasplenic primary tumors. We optimized several experimental variables, and found that the correct choice of cell line and the genetic background, as well as the age of the recipient mice, were critical for establishing a useful model system. Among a panel of colorectal cancer cell lines tested, the epithelial carcinoma HT29 line was found to be the most suitable in terms of producing homogeneous tumor growth and metastases. In our hands, SCID mice at the age of 125 days or older were the most suitable in supporting consistent HT29 tumor growth after splenic implantation followed by reproducible metastasis to the liver. A magnetic resonance imaging (MRI) protocol was optimized for use with this mouse model, and demonstrated to be a powerful method for analyzing the antitumor effects of an experimental therapy. Specifically, we used this system to with success to verify by MRI monitoring the efficacy of an intrasplenically administered oncolytic adenovirus therapy in reducing visceral tumor load and development of liver metastases. In summary, we have developed a highly optimized mouse model for liver metastasis of colorectal cancer, which allows detection of the tumor load at the whole body level and enables an accurate timing of therapeutic interventions to target different stages of cancer progression and metastatic development.
authors.affiliation: Cancer Gene Therapy Group, Molecular Cancer Biology Program, Transplantation Laboratory, Haartman Institute and Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland.
authors.forename: Sergio
authors.initials: S
authors.lastname: Lavilla-Alonso
authors.forename: Usama
authors.initials: U
authors.lastname: Abo-Ramadan
authors.forename: Juha
authors.initials: J
authors.lastname: Halavaara
authors.forename: Sophie
authors.initials: S
authors.lastname: Escutenaire
authors.forename: Turgut
authors.initials: T
authors.lastname: Tatlisumak
authors.forename: Kalle
authors.initials: K
authors.lastname: Saksela
authors.forename: Anna
authors.initials: A
authors.lastname: Kanerva
authors.forename: Akseli
authors.initials: A
authors.lastname: Hemminki
authors.forename: Sari
authors.initials: S
authors.lastname: Pesonen
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D016513:Mice, SCID; D009362:Neoplasm Metastasis / Q000473:pathology*; D009374:Neoplasms, Experimental / Q000628:therapy*
references.citation: Cancer J. 2010 Mar-Apr;16(2):103-10
references.pmid: 20404606
references.citation: Neoplasia. 2007 Jan;9(1):57-67
references.pmid: 17325744
references.citation: Nat Rev Cancer. 2009 Apr;9(4):302-12
references.pmid: 19308069
references.citation: World J Gastroenterol. 2009 Dec 14;15(46):5805-12
references.pmid: 19998501
references.citation: Am J Pathol. 2007 Mar;170(3):1077-85
references.pmid: 17322390
references.citation: Cancer Res. 2003 Nov 15;63(22):7785-90
references.pmid: 14633704
references.citation: Nat Rev Cancer. 2009 Apr;9(4):239-52
references.pmid: 19279573
references.citation: Eur Surg Res. 2009;42(3):195-200
references.pmid: 19270457
references.citation: J Exp Ther Oncol. 2002 Nov-Dec;2(6):337-49
references.pmid: 12440225
references.citation: Carcinogenesis. 2005 Mar;26(3):513-23
references.pmid: 15358632
references.citation: Cell Res. 2006 Aug;16(8):740
references.pmid: 16915293
references.citation: Nat Rev Cancer. 2009 Sep;9(9):665-74
references.pmid: 19693095
references.citation: Ann Surg Oncol. 2008 Nov;15(11):3308-15
references.pmid: 18685897
references.citation: Oncogene. 2004 Sep 23;23(44):7366-77
references.pmid: 15326482
references.citation: Lancet Oncol. 2007 May;8(5):444-8
references.pmid: 17466902
references.citation: Eur J Cancer. 2004 Apr;40(6):858-80
references.pmid: 15120042
references.citation: Cancer Res. 2004 Oct 1;64(19):7092-8
references.pmid: 15466205
references.citation: Nat Rev Cancer. 2009 Apr;9(4):274-84
references.pmid: 19308067
references.citation: Microvasc Res. 2007 Sep-Nov;74(2-3):72-84
references.pmid: 17560615
references.citation: Vet Pathol. 2006 Jul;43(4):401-23
references.pmid: 16846982
references.citation: Cancer Res. 2006 Dec 1;66(23):11293-7
references.pmid: 17145875
references.citation: Crit Rev Oncol Hematol. 2009 Oct;72(1):65-75
references.pmid: 19147371
references.citation: Cancer Res. 2002 Mar 1;62(5):1266-70
references.pmid: 11888888